Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

NuvoAir’s Inhaler Sensor Now Available in Europe

NuvoAir Aos, a sensor developed by NuvoAir that can track how inhalers are used by people with chronic obstructive pulmonary disease (COPD) or asthma, is now available in Europe, the company announced. The sensor is designated a Class I medical device in Europe, essentially indicating that it is…

Treatment With pMDI Ensifentrine Found to Improve Lung Function

Seven days of treatment with ensifentrine, given using a pressurized metered-dose inhaler — called a pMDI — resulted in marked lung function improvements in people with moderate to severe chronic obstructive pulmonary disease (COPD), according to data from a Phase 2 clinical trial. “This study demonstrates that ensifentrine administered…

MUC5AC Protein May Help Cause Thick, Sticky Mucus in Lungs

A mucus protein called MUC5AC may contribute to the abnormally thick and sticky mucus that develops in people with respiratory diseases such as chronic obstructive pulmonary disease (COPD), a new study shows. “MUC5AC seems to be crucial to the formation of stagnant, thicker mucus we see in pulmonary…

Zephyr Valve Now Covered By 2 More Blue Cross Blue Shield Plans

Two additional Blue Cross Blue Shield (BCBS) plans are now covering Pulmonx’s Zephyr Endobronchial Valve and similar devices to treat severe emphysema, a form of chronic obstructive pulmonary disease (COPD). With the addition of these two plans to similar previous policy decisions, valves will be now covered for the…

Renovion, COPD Foundation Partner on New Therapy to Clear Mucus

Renovion is teaming up with the COPD Foundation to develop a new nebulized therapy that aims to help clear mucus and reduce inflammation in people with chronic obstructive pulmonary disease (COPD) and non-cystic fibrosis bronchiectasis. Phase 2 clinical trials of the investigational treatment, called  ARINA-1, are planned to…